Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
1.
J Neurosci ; 32(32): 10887-94, 2012 Aug 08.
Artículo en Inglés | MEDLINE | ID: mdl-22875923

RESUMEN

Midbrain dopaminergic (mDA) neurons control movement and emotion, and their degeneration leads to motor and cognitive defects in Parkinson's disease (PD). miR-133b is a conserved microRNA that is thought to regulate mDA neuron differentiation by targeting Pitx3, a transcription factor required for appropriate development of mDA substantia nigra neurons. Moreover, miR-133b has been found to be depleted in the midbrain of PD patients. However, the function of miR-133b in the intact midbrain has not been determined. Here we show that miR-133b null mice have normal numbers of mDA neurons during development and aging. Dopamine levels are unchanged in the striatum, while expression of dopaminergic genes, including Pitx3, is also unaffected. Finally, motor coordination and both spontaneous and psychostimulant-induced locomotion are unaltered in miR-133b null mice, suggesting that miR-133b does not play a significant role in mDA neuron development and maintenance in vivo.


Asunto(s)
Conducta Animal/fisiología , Dopamina/metabolismo , Neuronas Dopaminérgicas/fisiología , Regulación del Desarrollo de la Expresión Génica/genética , Mesencéfalo/citología , MicroARNs/metabolismo , Factores de Edad , Análisis de Varianza , Animales , Animales Recién Nacidos , Recuento de Células , Colina O-Acetiltransferasa/metabolismo , Cromatografía Liquida , Adaptación a la Oscuridad/genética , Técnicas Electroquímicas , Conducta Exploratoria/fisiología , Glutamato Descarboxilasa/metabolismo , Proteínas de Homeodominio/metabolismo , Masculino , Aprendizaje por Laberinto/fisiología , Mesencéfalo/crecimiento & desarrollo , Ratones , Ratones Noqueados , Ratones Mutantes Neurológicos , MicroARNs/genética , Microdiálisis , Actividad Motora/genética , Desempeño Psicomotor/fisiología , Técnicas Estereotáxicas , Factores de Transcripción/metabolismo , Tirosina 3-Monooxigenasa/metabolismo
2.
J Neurosci ; 32(5): 1545-59, 2012 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-22302798

RESUMEN

The A/VN/1203/04 strain of the H5N1 influenza virus is capable of infecting the CNS of mice and inducing a number of neurodegenerative pathologies. Here, we examined the effects of H5N1 on several pathological aspects affected in parkinsonism, including loss of the phenotype of dopaminergic neurons located in the substantia nigra pars compacta (SNpc), expression of monoamines and indolamines in brain, alterations in SNpc microglia number and morphology, and expression of cytokines, chemokines, and growth factors. We find that H5N1 induces a transient loss of the dopaminergic phenotype in SNpc and now report that this loss recovers by 90 d after infection. A similar pattern of loss and recovery was seen in monoamine levels of the basal ganglia. The inflammatory response in lung and different regions of the brain known to be targets of the H5N1 virus (brainstem, substantia nigra, striatum, and cortex) were examined at 3, 10, 21, 60, and 90 d after infection. In each of these brain regions, we found a significant increase in the number of activated microglia that lasted at least 90 d. We also quantified expression of IL-1α, IL-1ß, IL-2, IL-6, IL-9, IL-10, IL-12(p70), IL-13, TNF-α, IFN-γ, granulocyte-macrophage colony-stimulating factor, granulocyte colony-stimulating factor, macrophage colony-stimulating factor, eotaxin, interferon-inducible protein 10, cytokine-induced neutrophil chemoattractant, monocyte chemotactic protein-1, macrophage inflammatory protein (MIP) 1α, MIP-1ß, and VEGF, and found that the pattern and levels of expression are dependent on both brain region and time after infection. We conclude that H5N1 infection in mice induces a long-lasting inflammatory response in brain and may play a contributing factor in the development of pathologies in neurodegenerative disorders.


Asunto(s)
Enfermedades Virales del Sistema Nervioso Central/patología , Mediadores de Inflamación/efectos adversos , Subtipo H5N1 del Virus de la Influenza A/patogenicidad , Gripe Humana/patología , Animales , Encéfalo/metabolismo , Encéfalo/patología , Encéfalo/virología , Enfermedades Virales del Sistema Nervioso Central/metabolismo , Enfermedades Virales del Sistema Nervioso Central/virología , Embrión de Pollo , Femenino , Humanos , Inflamación/patología , Inflamación/virología , Mediadores de Inflamación/metabolismo , Gripe Humana/metabolismo , Gripe Humana/virología , Ratones , Ratones Endogámicos C57BL
3.
Hum Mol Genet ; 19(9): 1633-50, 2010 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-20106867

RESUMEN

Parkinson disease (PD) is a neurodegenerative disease with motor as well as non-motor signs in the gastrointestinal tract that include dysphagia, gastroparesis, prolonged gastrointestinal transit time, constipation and difficulty with defecation. The gastrointestinal dysfunction commonly precedes the motor symptoms by decades. Most PD is sporadic and of unknown etiology, but a fraction is familial. Among familial forms of PD, a small fraction is caused by missense (A53T, A30P and E46K) and copy number mutations in SNCA which encodes alpha-synuclein, a primary protein constituent of Lewy bodies, the pathognomonic protein aggregates found in neurons in PD. We set out to develop transgenic mice expressing mutant alpha-synuclein (either A53T or A30P) from insertions of an entire human SNCA gene as models for the familial disease. Both the A53T and A30P lines show robust abnormalities in enteric nervous system (ENS) function and synuclein-immunoreactive aggregates in ENS ganglia by 3 months of age. The A53T line also has abnormal motor behavior but neither demonstrates cardiac autonomic abnormalities, olfactory dysfunction, dopaminergic neurotransmitter deficits, Lewy body inclusions or neurodegeneration. These animals recapitulate the early gastrointestinal abnormalities seen in human PD. The animals also serve as an in vivo system in which to investigate therapies for reversing the neurological dysfunction that target alpha-synuclein toxicity at its earliest stages.


Asunto(s)
Sistema Nervioso Central/patología , Modelos Animales de Enfermedad , Sistema Nervioso Entérico/anomalías , Mutación/genética , Enfermedad de Parkinson/genética , alfa-Sinucleína/genética , Factores de Edad , Animales , Western Blotting , Cromatografía Líquida de Alta Presión , Cartilla de ADN/genética , Dopamina/metabolismo , Humanos , Inmunohistoquímica , Hibridación Fluorescente in Situ , Ratones , Ratones Transgénicos , Actividad Motora/fisiología , Mutagénesis , Enfermedad de Parkinson/patología , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Prueba de Desempeño de Rotación con Aceleración Constante , alfa-Sinucleína/metabolismo
4.
Proc Natl Acad Sci U S A ; 106(8): 2933-8, 2009 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-19196989

RESUMEN

Oxidative stress has been implicated in the etiology of Parkinson's disease (PD) and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of PD. It is known that under conditions of oxidative stress, the transcription factor NF-E2-related factor (Nrf2) binds to antioxidant response element (ARE) to induce antioxidant and phase II detoxification enzymes. To investigate the role of Nrf2 in the process of MPTP-induced toxicity, mice expressing the human placental alkaline phosphatase (hPAP) gene driven by a promoter containing a core ARE sequence (ARE-hPAP) were used. ARE-hPAP mice were injected (30 mg/kg) once per day for 5 days and killed 7 days after the last MPTP injection. In response to this design, ARE-dependent gene expression was decreased in striatum whereas it was increased in substantia nigra. The same MPTP protocol was applied in Nrf2(+/+) and Nrf2(-/-) mice; Nrf2 deficiency increases MPTP sensitivity. Furthermore, we evaluated the potential for astrocytic Nrf2 overexpression to protect from MPTP toxicity. Transgenic mice with Nrf2 under control of the astrocyte-specific promoter for the glial fribillary acidic protein (GFAP-Nrf2) on both a Nrf2(+/+) and Nrf2(-/-) background were administered MPTP. In the latter case, only the astrocytes expressed Nrf2. Independent of background, MPTP-mediated toxicity was abolished in GFAP-Nrf2 mice. These striking results indicate that Nrf2 expression restricted to astrocytes is sufficient to protect against MPTP and astrocytic modulation of the Nrf2-ARE pathway is a promising target for therapeutics aimed at reducing or preventing neuronal death in PD.


Asunto(s)
Astrocitos/patología , Modelos Animales de Enfermedad , Intoxicación por MPTP/fisiopatología , Factor 2 Relacionado con NF-E2/fisiología , Enfermedad de Parkinson/fisiopatología , 1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/farmacología , Fosfatasa Alcalina/genética , Animales , Secuencia de Bases , Cuerpo Estriado/efectos de los fármacos , Cuerpo Estriado/patología , Cartilla de ADN , Proteína Ácida Fibrilar de la Glía/genética , Inmunohistoquímica , Intoxicación por MPTP/patología , Ratones , Ratones Transgénicos , Factor 2 Relacionado con NF-E2/genética , Enfermedad de Parkinson/patología , Sustancia Negra/efectos de los fármacos , Sustancia Negra/patología
5.
Int J Neurosci ; 119(9): 1362-83, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19922362

RESUMEN

Dynorphin (DYN) fragments are the members of the endogenous opioid system and postulated ligands for the opioid receptors. Infusion of DYN(1-17) fragment into the rat dorsal striatum caused a significant increase in acetylcholine and decrease in dopamine overflow. Contrary to this, infusions of DYN(2-17) fragment into the rat dorsal striatum caused a significant increase in dopamine and decrease in acetylcholine overflow. Intrastriatal infusions of different doses of the acetylcholinesterase blocker, neostigmine, augmented acetylcholine and inhibited dopamine overflow in a dose-dependent manner. The opposing responses of the DYN fragments suggest that the N-terminal residue plays a key role in presynaptic neuromodulation.


Asunto(s)
Acetilcolina/metabolismo , Química Encefálica/efectos de los fármacos , Dopamina/metabolismo , Dinorfinas/farmacología , Neostriado/fisiología , Animales , Inhibidores de la Colinesterasa/farmacología , Cromatografía Líquida de Alta Presión , Dinorfinas/administración & dosificación , Electroquímica , Masculino , Microdiálisis , Microinyecciones , Neostigmina/farmacología , Neostriado/anatomía & histología , Fragmentos de Péptidos/administración & dosificación , Fragmentos de Péptidos/farmacología , Ratas , Ratas Sprague-Dawley , Receptores Presinapticos/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos
6.
Science ; 356(6345): 1352-1356, 2017 06 30.
Artículo en Inglés | MEDLINE | ID: mdl-28663494

RESUMEN

Circuits in the auditory cortex are highly susceptible to acoustic influences during an early postnatal critical period. The auditory cortex selectively expands neural representations of enriched acoustic stimuli, a process important for human language acquisition. Adults lack this plasticity. Here we show in the murine auditory cortex that juvenile plasticity can be reestablished in adulthood if acoustic stimuli are paired with disruption of ecto-5'-nucleotidase-dependent adenosine production or A1-adenosine receptor signaling in the auditory thalamus. This plasticity occurs at the level of cortical maps and individual neurons in the auditory cortex of awake adult mice and is associated with long-term improvement of tone-discrimination abilities. We conclude that, in adult mice, disrupting adenosine signaling in the thalamus rejuvenates plasticity in the auditory cortex and improves auditory perception.


Asunto(s)
Adenosina/metabolismo , Corteza Auditiva/metabolismo , Transducción de Señal , 5'-Nucleotidasa/metabolismo , Adenosina/administración & dosificación , Adenosina/análogos & derivados , Agonistas del Receptor de Adenosina A1/administración & dosificación , Antagonistas del Receptor de Adenosina A1/administración & dosificación , Animales , Percepción Auditiva , Proteínas Ligadas a GPI/metabolismo , Ratones , Plasticidad Neuronal , Piperidinas/administración & dosificación , Piridazinas/administración & dosificación , Receptor de Adenosina A1/metabolismo , Tálamo/metabolismo
7.
J Parkinsons Dis ; 5(2): 389-401, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25633843

RESUMEN

BACKGROUND: MPTP and paraquat are two compounds that have been used to model Parkinson's disease in mice. Previous studies in two non-traditional strains of mice have shown that a single dose of MPTP can induce changes in body temperature, while the effects of paraquat have not been examined. Examination of body temperature is important since small fluctuations in an animal's core temperature can significantly affect drug metabolism, and if significant enough can even culminate in an animal's death. OBJECTIVE: To determine how external heating can alter the survival of C57BL/6J mice following MPTP administration. METHODS: In this study, we examine the effects of MPTP (4×20 mg/kg, 2 hours apart) and paraquat (2×10 mg/kg/week for 3 weeks) on core temperature of C57BL/6J mice. Correlations of purine and catecholamine levels were also done in mice treated with MPTP. RESULTS: We find that MPTP induces a significant hypothermia in C57BL/6J mice that reduces their core temperature below the limit of fatal hypothermia. Unlike MPTP, paraquat did not induce a significant hypothermia. Placement of animals on heating pads significantly abrogates the loss of core temperature. In both heated and non-heated conditions, mice treated with MPTP showed a significant depletion of ATP within 2 hours of administration in both striatum and SN that started to recover 2 hours after MPTP administration was complete. Striatal DA and DOPAC are significantly reduced starting 4-6 hours after MPTP. CONCLUSIONS: The fatal hypothermic effects of MPTP can be abrogated through use of external heating.


Asunto(s)
Temperatura Corporal/efectos de los fármacos , Modelos Animales de Enfermedad , Intoxicación por MPTP/fisiopatología , Paraquat/toxicidad , Animales , Cuerpo Estriado/efectos de los fármacos , Intoxicación por MPTP/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Paraquat/metabolismo , Trastornos Parkinsonianos/inducido químicamente , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/fisiopatología , Purinas/metabolismo , Sustancia Negra/efectos de los fármacos
8.
PLoS One ; 9(3): e92422, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24642754

RESUMEN

Adenosine (ADO), a non-classical neurotransmitter and neuromodulator, and its metabolites adenosine triphosphate (ATP), adenosine diphosphate (ADP) and adenosine monophosphate (AMP), have been shown to play an important role in a number of biochemical processes. Although their signaling is well described, it has been difficult to directly, accurately and simultaneously quantitate these purines in tissue or fluids. Here, we describe a novel method for measuring adenosine (ADO) and its metabolites using high performance liquid chromatography with electrochemical detection (HPLC-ECD). Using this chromatographic technique, we examined baseline levels of ADO and ATP, ADP and AMP in 6 different brain regions of the C57BL/6J mouse: stratum, cortex, hippocampus, olfactory bulb, substantia nigra and cerebellum and compared ADO levels in 5 different strains of mice (C57BL/6J, Swiss-Webster, FVB/NJ, 129P/J, and BALB/c). These studies demonstrate that baseline levels of purines vary significantly among the brain regions as well as between different mouse strains. These dissimilarities in purine concentrations may explain the variable phenotypes among background strains described in neurological disease models.


Asunto(s)
Adenosina/metabolismo , Encéfalo/metabolismo , Neurotransmisores/metabolismo , Adenosina/aislamiento & purificación , Adenosina Difosfato/aislamiento & purificación , Adenosina Difosfato/metabolismo , Adenosina Monofosfato/aislamiento & purificación , Adenosina Monofosfato/metabolismo , Adenosina Trifosfato/aislamiento & purificación , Adenosina Trifosfato/metabolismo , Animales , Cromatografía Líquida de Alta Presión/normas , Técnicas Electroquímicas/normas , Masculino , Ratones , Ratones de la Cepa 129 , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Neurotransmisores/aislamiento & purificación , Especificidad de Órganos , Estándares de Referencia
9.
Science ; 344(6188): 1178-82, 2014 Jun 06.
Artículo en Inglés | MEDLINE | ID: mdl-24904170

RESUMEN

Auditory hallucinations in schizophrenia are alleviated by antipsychotic agents that inhibit D2 dopamine receptors (Drd2s). The defective neural circuits and mechanisms of their sensitivity to antipsychotics are unknown. We identified a specific disruption of synaptic transmission at thalamocortical glutamatergic projections in the auditory cortex in murine models of schizophrenia-associated 22q11 deletion syndrome (22q11DS). This deficit is caused by an aberrant elevation of Drd2 in the thalamus, which renders 22q11DS thalamocortical projections sensitive to antipsychotics and causes a deficient acoustic startle response similar to that observed in schizophrenic patients. Haploinsufficiency of the microRNA-processing gene Dgcr8 is responsible for the Drd2 elevation and hypersensitivity of auditory thalamocortical projections to antipsychotics. This suggests that Dgcr8-microRNA-Drd2-dependent thalamocortical disruption is a pathogenic event underlying schizophrenia-associated psychosis.


Asunto(s)
Síndrome de Deleción 22q11/genética , Corteza Auditiva/metabolismo , Haploinsuficiencia , Proteínas de Unión al ARN/genética , Receptores de Dopamina D2/biosíntesis , Esquizofrenia/genética , Tálamo/metabolismo , Síndrome de Deleción 22q11/tratamiento farmacológico , Animales , Antipsicóticos/uso terapéutico , Modelos Animales de Enfermedad , Resistencia a Medicamentos/genética , Ratones , Ratones Mutantes , MicroARNs/metabolismo , Receptores de Dopamina D2/genética , Esquizofrenia/tratamiento farmacológico , Transmisión Sináptica/genética
10.
PLoS One ; 7(3): e33693, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22470460

RESUMEN

BACKGROUND: Methylphenidate (MPH) is a psychostimulant that exerts its pharmacological effects via preferential blockade of the dopamine transporter (DAT) and the norepinephrine transporter (NET), resulting in increased monoamine levels in the synapse. Clinically, methylphenidate is prescribed for the symptomatic treatment of ADHD and narcolepsy; although lately, there has been an increased incidence of its use in individuals not meeting the criteria for these disorders. MPH has also been misused as a "cognitive enhancer" and as an alternative to other psychostimulants. Here, we investigate whether chronic or acute administration of MPH in mice at either 1 mg/kg or 10 mg/kg, affects cell number and gene expression in the basal ganglia. METHODOLOGY/PRINCIPAL FINDINGS: Through the use of stereological counting methods, we observed a significant reduction (∼20%) in dopamine neuron numbers in the substantia nigra pars compacta (SNpc) following chronic administration of 10 mg/kg MPH. This dosage of MPH also induced a significant increase in the number of activated microglia in the SNpc. Additionally, exposure to either 1 mg/kg or 10 mg/kg MPH increased the sensitivity of SNpc dopaminergic neurons to the parkinsonian agent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Unbiased gene screening employing Affymetrix GeneChip® HT MG-430 PM revealed changes in 115 and 54 genes in the substantia nigra (SN) of mice exposed to 1 mg/kg and 10 mg/kg MPH doses, respectively. Decreases in the mRNA levels of gdnf, dat1, vmat2, and th in the substantia nigra (SN) were observed with both acute and chronic dosing of 10 mg/kg MPH. We also found an increase in mRNA levels of the pro-inflammatory genes il-6 and tnf-α in the striatum, although these were seen only at an acute dose of 10 mg/kg and not following chronic dosing. CONCLUSION: Collectively, our results suggest that chronic MPH usage in mice at doses spanning the therapeutic range in humans, especially at prolonged higher doses, has long-term neurodegenerative consequences.


Asunto(s)
Ganglios Basales/metabolismo , Neuronas Dopaminérgicas/efectos de los fármacos , Metilfenidato/farmacología , Microglía/efectos de los fármacos , Animales , Ganglios Basales/citología , Estimulantes del Sistema Nervioso Central/farmacología , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/genética , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Neuronas Dopaminérgicas/citología , Perfilación de la Expresión Génica , Factor Neurotrófico Derivado de la Línea Celular Glial/genética , Factor Neurotrófico Derivado de la Línea Celular Glial/metabolismo , Interleucina-6/genética , Interleucina-6/metabolismo , Ratones , Microglía/citología , Análisis de Secuencia por Matrices de Oligonucleótidos , Sustancia Negra/metabolismo , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo , Proteínas de Transporte Vesicular de Monoaminas/genética , Proteínas de Transporte Vesicular de Monoaminas/metabolismo
11.
PLoS One ; 7(11): e50040, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-23209637

RESUMEN

Restorative/protective therapies to restore dopamine neurons in the substantia nigra pars compacta (SNpc) are greatly needed to effectively change the debilitating course of Parkinson's disease. In this study, we tested the therapeutic potential of a neurogenic neurosteroid, allopregnanolone, in the restoration of the components of the nigrostriatal pathway in MPTP-lesioned mice by measuring striatal dopamine levels, total and tyrosine hydroxylase immunoreactive neuron numbers and BrdU-positive cells in the SNpc. An acute treatment (once/week for two weeks) with allopregnanolone restored the number of tyrosine hydroxylase-positive and total cell numbers in the SNpc of MPTP-lesioned mice, even though this did not increase striatal dopamine. It was also noted that MPTP treated mice to which allopregnanolone was administered had an increase in BrdU-positive cells in the SNpc. The effects of allopregnanolone in MPTP-lesioned mice were more apparent in mice that underwent behavioral tests. Interestingly, mice treated with allopregnanolone after MPTP lesion were able to perform at levels similar to that of non-lesioned control mice in a rotarod test. These data demonstrate that allopregnanolone promotes the restoration of tyrosine hydroxylase immunoreactive neurons and total cells in the nigrostriatal tract, improves the motor performance in MPTP-treated mice, and may serve as a therapeutic strategy for Parkinson's disease.


Asunto(s)
Intoxicación por MPTP/metabolismo , Intoxicación por MPTP/fisiopatología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Pregnanolona/farmacología , Desempeño Psicomotor/efectos de los fármacos , Tirosina 3-Monooxigenasa/metabolismo , Animales , Modelos Animales de Enfermedad , Dopamina/metabolismo , Masculino , Mesencéfalo/efectos de los fármacos , Mesencéfalo/metabolismo , Ratones , Norepinefrina/metabolismo , Sustancia Negra/efectos de los fármacos , Sustancia Negra/metabolismo
12.
Cancer Cell ; 20(2): 260-75, 2011 Aug 16.
Artículo en Inglés | MEDLINE | ID: mdl-21840489

RESUMEN

It is widely believed that the molecular and cellular features of a tumor reflect its cell of origin and can thus provide clues about treatment targets. The retinoblastoma cell of origin has been debated for over a century. Here, we report that human and mouse retinoblastomas have molecular, cellular, and neurochemical features of multiple cell classes, principally amacrine/horizontal interneurons, retinal progenitor cells, and photoreceptors. Importantly, single-cell gene expression array analysis showed that these multiple cell type-specific developmental programs are coexpressed in individual retinoblastoma cells, which creates a progenitor/neuronal hybrid cell. Furthermore, neurotransmitter receptors, transporters, and biosynthetic enzymes are expressed in human retinoblastoma, and targeted disruption of these pathways reduces retinoblastoma growth in vivo and in vitro.


Asunto(s)
Retinoblastoma/patología , Animales , Diferenciación Celular/genética , Perfilación de la Expresión Génica , Genotipo , Humanos , Ratones , Retinoblastoma/genética
13.
Brain Res ; 1341: 72-83, 2010 Jun 23.
Artículo en Inglés | MEDLINE | ID: mdl-20116369

RESUMEN

Exercise has been shown to be potently neuroprotective in several neurodegenerative models, including 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) model of Parkinson's disease (PD). In order to determine the critical duration of exercise necessary for DA neuroprotection, mice were allowed to run for either 1, 2 or 3months prior to treatment with saline or MPTP. Quantification of DA neurons in the SNpc show that mice allowed to run unrestricted for 1 or 2months lost significant numbers of neurons following MPTP administration as compared to saline treated mice; however, 3months of exercise provided complete protection against MPTP-induced neurotoxicity. To determine the critical intensity of exercise for DA neuroprotection, mice were restricted in their running to either 1/3 or 2/3 that of the full running group for 3months prior to treatment with saline or MPTP. Quantification of DA neurons in the SNpc show that mice whose running was restricted lost significant numbers of DA neurons due to MPTP toxicity; however, the 2/3 running group demonstrated partial protection. Neurochemical analyses of DA and its metabolites DOPAC and HVA show that exercise also functionally protects neurons from MPTP-induced neurotoxicity. Proteomic analysis of SN and STR tissues indicates that 3months of exercise induces changes in proteins related to energy regulation, cellular metabolism, the cytoskeleton, and intracellular signaling events. Taken together, these data indicate that exercise potently protects DA neurons from acute MPTP toxicity, suggesting that this simple lifestyle element may also confer significant protection against developing PD in humans.


Asunto(s)
1-Metil-4-fenil-1,2,3,6-Tetrahidropiridina/administración & dosificación , Citoprotección/fisiología , Neurotoxinas/administración & dosificación , Trastornos Parkinsonianos/prevención & control , Trastornos Parkinsonianos/terapia , Condicionamiento Físico Animal/fisiología , Animales , Modelos Animales de Enfermedad , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Degeneración Nerviosa/fisiopatología , Degeneración Nerviosa/prevención & control , Degeneración Nerviosa/terapia , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Neuronas/patología , Trastornos Parkinsonianos/fisiopatología , Sustancia Negra/efectos de los fármacos , Sustancia Negra/metabolismo , Sustancia Negra/patología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA